Table 1. Protease inhibition, cytotoxicity, and broad-spectrum anti-flavivirus activities.
| Compound | IC50-pro≠ (μM) | CC50≠ (μM) | Virus | EC50≠ (μM) | EC90≠ (μM) | TI# |
|---|---|---|---|---|---|---|
| temoporfin | 1.1 ± 0.1 | 40.7 ± 0.7 | ZIKV | 0.024 ± 0.003 | 0.13 | 1 696 |
| ZIKV* | 0.022 ± 0.002 | 0.12 | 1 850 | |||
| DENV2 | 0.020 ± 0.003 | 0.11 | 2 035 | |||
| WNV* | 0.010 ± 0.001 | 0.030 | 4 070 | |||
| JEV* | 0.011 ± 0.001 | 0.025 | 3 700 | |||
| YFV* | 0.006 ± 0.001 | 0.015 | 6 783 | |||
| niclosamide | 12.3 ± 0.6 | 4.8 ± 1.0 | ZIKV | 0.48 ± 0.06 | 1.9 | 10 |
| DENV2 | 0.55 ± 0.05 | 2.3 | 9 | |||
| WNV | 0.54 ± 0.17 | 2.3 | 9 | |||
| JEV | 1.02 ± 0.08 | 2.4 | 3.8 | |||
| YFV | 0.84 ± 0.02 | 1.9 | 5.7 | |||
| nitazoxanide | 15.9 ± 0.9 | 77 ± 7.2 | ZIKV | 1.48 ± 0.18 | 4.0 | 52 |
| 6054 | JEV | 0.3954 | 15454 |
*Experiment was performed without ambient light (in dark).
IC50-pro≠, compound concentration required to inhibit 50% of a reaction or binding; CC50≠: the concentration of compound at which 50% cells are viable; EC50≠ and EC90≠: the effective concentration of a drug at which virus production is reduced by 50% or 90%, respectively.
TI#, therapeutic index defined as CC50/EC50.